Home Cart 0 Sign in  
X

[ CAS No. 34784-05-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 34784-05-9
Chemical Structure| 34784-05-9
Chemical Structure| 34784-05-9
Structure of 34784-05-9 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 34784-05-9 ]

Related Doc. of [ 34784-05-9 ]

Alternatived Products of [ 34784-05-9 ]
Product Citations

Product Details of [ 34784-05-9 ]

CAS No. :34784-05-9 MDL No. :MFCD04973299
Formula : C9H6BrN Boiling Point : -
Linear Structure Formula :- InChI Key :ZTEATMVVGQUULZ-UHFFFAOYSA-N
M.W : 208.05 Pubchem ID :313681
Synonyms :
NSC 229320

Calculated chemistry of [ 34784-05-9 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 0.0
Molar Refractivity : 49.44
TPSA : 12.89 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.48 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.05
Log Po/w (XLOGP3) : 2.94
Log Po/w (WLOGP) : 3.0
Log Po/w (MLOGP) : 2.3
Log Po/w (SILICOS-IT) : 3.17
Consensus Log Po/w : 2.69

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.65
Solubility : 0.0461 mg/ml ; 0.000221 mol/l
Class : Soluble
Log S (Ali) : -2.87
Solubility : 0.279 mg/ml ; 0.00134 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.56
Solubility : 0.00574 mg/ml ; 0.0000276 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.23

Safety of [ 34784-05-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P305+P351+P338 UN#:N/A
Hazard Statements:H302-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 34784-05-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 34784-05-9 ]
  • Downstream synthetic route of [ 34784-05-9 ]

[ 34784-05-9 ] Synthesis Path-Upstream   1~26

  • 1
  • [ 1122-62-9 ]
  • [ 34784-05-9 ]
  • [ 42398-73-2 ]
Reference: [1] Organic Letters, 2018,
  • 2
  • [ 34784-05-9 ]
  • [ 7651-82-3 ]
YieldReaction ConditionsOperation in experiment
75% With tris-(dibenzylideneacetone)dipalladium(0); potassium hydroxide; tert-butyl XPhos In 1,4-dioxane; water at 100℃; for 1.5 h; AB21-1 (lg, 4.83 mmol) was dissolved in dioxane (5 mL) Adding tris (dibenzylideneacetone) dipalladium (lllmg, 0.19 mmol) and 2-di-tert-butylphosphine 2 ', 4', 6'-triisopropylbiphenyl (82 mg, 0.19 mmol) Then, potassium hydroxide (812 mg, 14.49 mmol) dissolved in 5 mL of water was added and heated to 100 ° C for 1.5 hours. After cooling to room temperature, 2N HCl (20 mL) was added, stirred for 1 hour, concentrated under reduced pressure, extracted with dichloromethane (30 mL * 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give a pale yellow solid (526 mg, 75percent).
Reference: [1] Patent: CN104876912, 2017, B, . Location in patent: Paragraph 0047; 0169-0172
  • 3
  • [ 34784-05-9 ]
  • [ 23687-26-5 ]
YieldReaction ConditionsOperation in experiment
85% With ammonium hydroxide; copper(ll) sulfate pentahydrate In water at 190℃; for 6 h; Reference Example 1
Synthesis of 6-aminoisoquinoline (Reference Compound 1)
6-bromoisoquinoline that weighed 17.2 g (see WO 2008/077553), 200 mL of 28percent ammonia water and 10.8 g of copper (II) sulfate pentahydrate were put into the autoclave and tightly sealed, and the mixture was then stirred at 190° C. for 6 hours.
After cooling to room temperature, the reaction solution was poured into 250 mL of a 10percent aqueous sodium hydroxide solution, followed by extraction with ethyl acetate (100 mL*5).
The extract was dried over anhydrous sodium sulfate, filtered, and then concentrated.
The obtained crude product was suspended in dichloromethane and then filtered to obtain 10.2 g of the compound of interest as a light brown crystal (85percent).
1H-NMR spectrum (CDCl3, δ ppm): 5.54 (br s, 2H), 6.58 (s, 1H), 7.00 (d, J=9.0 Hz, 1H), 7.35 (d, J=5.5 Hz, 1H), 7.75 (d, J=9.0 Hz, 1H), 8.32 (d, J=5.5 Hz, 1H), 8.98 (s, 1H)
Reference: [1] Patent: US2012/35159, 2012, A1, . Location in patent: Page/Page column 8
  • 4
  • [ 557-21-1 ]
  • [ 34784-05-9 ]
  • [ 106778-42-1 ]
YieldReaction ConditionsOperation in experiment
83% at 100℃; for 3.5 h; Preparation Example G-1. Isoquinoline-6-carboxylic acid A solution prepared by adding (4-bromobenzylydene)-(2,2-diethoxyethyl) amine (synthesized from 4-bromobenzaldehyde, according to the method described in J. Org. Chem., vol. 48, 3344-3346 (1983)) (51.4g, 0.189mmol) to an ice-cold concentrated sulfuric acid (20g) was added to a solution prepared by adding diphosphorus pentoxide (40g) to an ice-cold concentrated sulfuric acid (360g), and the solution was stirred at 160°C for 2 hours. The reaction solution was gradually cooled to 0°C, the solution was filtered through Celite pad, the filtrate was neutralized with sodium carbonate. This solution was further filtrated through Celite pad, this filtrate was extracted with ethyl acetate and dried over anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate), and 6-bromoisoquinoline (482mg, 1.2percent) was obtained as an orange oil. Next, to a solution of 6-bromoisoquinoline (382mg, 1.84mmol) in N,N-dimethylformamide (3.8mL) were added zinc cyanide (431 mg, 3.67mmol) and tetrakis(triphenylphosphine)palladium(0) (42mg, 0.0367mmol) under nitrogen atmosphere, and the mixture was stirred at 100°C for 1 hour. Tetrakis(triphenylphosphine)palladium(0) (42mg, 0.0367mmol) was further added, and the mixture was stirred for 2.5 hours at 100°C. The reaction mixture was allowed to room temperature, ethyl acetate and water were added for extraction, the organic layer was washed with water and dried over anhydrous magnesium sulfate. The residue was purified by silica gel column chromatography (hexane : ethyl acetate), and isoquinoline-6-carbonitrile (234mg, 83percent) was obtained as a yellow solid. Lastly, isoquinoline-6-carbonitrile (51mg, 0.331 mmol) was dissolved in diethyleneglycol (1.0mL), potassium hydroxide (9mg, 0.166mmol) was added thereto, followed by stirring at 160°C for 3 hours. The reaction mixture was allowed to room temperature, neutralized using hydrochloric acid, extracted with ethyl acetate, dried over anhydrous magnesium sulfate, then, the solvent was evaporated. Water was added to the residue, the precipitated solid was collected, washed with water, dried in vacuo, so as to obtain the title compound (12mg, 21 percent) as a yellow solid.
78% With tetrakis(triphenylphosphine) palladium(0) In N,N-dimethyl-formamide at 90℃; for 24 h; Inert atmosphere To a suspension of 6-bromoisoquinoline (624 mg, 3.0 mmol) and Pd(PPh3)4 (173 mg, 0.15 mmol) in DMF (6 mL) was added Zn(CN)2 (210 mg, 1.8 mmol), and the reaction mixture was stirred at 90 °C under N2 for 24 h. After cooling to room temperature, H2O (40 mL) was added and the mixture was extracted with ethyl acetate (40 mL x 3). The combined organic layers were washed with brine (30 mL x 3) and dried over Na2SO4. After concentration and purification by column chromatography (petroleum ether/ethylacetate = 3:1), 55 was obtained as a white solid (360 mg, 78percent). 1H NMR (400 MHz, CDCl3) d 9.37 (s, 1H), 8.70 (d, J = 5.6 Hz, 1H),8.25 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.73(d, J = 5.6 Hz, 1H).
Reference: [1] Patent: EP1782811, 2007, A1, . Location in patent: Page/Page column 58
[2] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 22, p. 5861 - 5872
  • 5
  • [ 34784-05-9 ]
  • [ 557-21-1 ]
  • [ 106778-42-1 ]
YieldReaction ConditionsOperation in experiment
83% at 100℃; for 3.5 h; A solution prepared by adding (4-bromobenzylydene)-(2,2-diethoxyethyl) amine (synthesized from 4-bromobenzaldehyde, according to the method described in J. Org. Chem., vol. 48, 3344-3346 (1983)) (51.4g, 0.189mmol) to an ice-cold concentrated sulfuric acid (20g) was added to a solution prepared by adding diphosphorus pentoxide (40g) to an ice-cold concentrated sulfuric acid (360g), and the solution was stirred at 160°C for 2 hours. The reaction solution was gradually cooled to 0°C, the solution was filtered through Celite pad, the filtrate was neutralized with sodium carbonate. This solution was further filtrated through Celite pad, this filtrate was extracted with ethyl acetate and dried over anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate), and 6-bromoisoquinoline (482mg, 1.2percent) was obtained as an orange oil. Next, to a solution of 6-bromoisoquinoline (382mg, 1.84mmol) in N,N-dimethylformamide (3.8mL) were added zinc cyanide (431mg, 3.67mmol) and tetrakis(triphenylphosphine)palladium(0) (42mg, 0.0367mmol) under nitrogen atmosphere, and the mixture was stirred at 100°C for 1 hour. Tetrakis(triphenylphosphine)palladium(0) (42mg, 0.0367mmol) was further added, and the mixture was stirred for 2.5 hours at 100°C. The reaction mixture was allowed to room temperature, ethyl acetate and water were added for extraction, the organic layer was washed with water and dried over anhydrous magnesium sulfate. The residue was purified by silica gel column chromatography (hexane : ethyl acetate), and isoquinoline-6-carbonitrile (234mg, 83percent) was obtained as a yellow solid. Lastly, isoquinoline-6-carbonitrile (51mg, 0.331 mmol) was dissolved in diethyleneglycol (1.0mL), potassium hydroxide (9mg, 0.166mmol) was added thereto, followed by stirring at 160°C for 3 hours. The reaction mixture was allowed to room temperature, neutralized using hydrochloric acid, extracted with ethyl acetate, dried over anhydrous magnesium sulfate, then, the solvent was evaporated. Water was added to the residue, the precipitated solid was collected, washed with water, dried in vacuo, so as to obtain the title compound (12mg, 21 percent) as a yellow solid.
Reference: [1] Patent: EP1669348, 2006, A1, . Location in patent: Page/Page column 66
  • 6
  • [ 34784-05-9 ]
  • [ 106778-42-1 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 5, p. 1559 - 1564
[2] Patent: CN106831575, 2017, A, . Location in patent: Paragraph 0020; 0023
  • 7
  • [ 34784-05-9 ]
  • [ 544-92-3 ]
  • [ 106778-42-1 ]
Reference: [1] Patent: WO2009/11880, 2009, A2, . Location in patent: Page/Page column 97
  • 8
  • [ 34784-05-9 ]
  • [ 106778-43-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 1999, vol. 9, # 17, p. 2583 - 2586
[2] Journal of the American Chemical Society, 1939, vol. 61, p. 183
[3] Patent: CN106831575, 2017, A,
  • 9
  • [ 1122-91-4 ]
  • [ 22483-09-6 ]
  • [ 34784-05-9 ]
YieldReaction ConditionsOperation in experiment
35%
Stage #1: for 12 h; Reflux; Dean-Stark
Stage #2: With chloroformic acid ethyl ester In tetrahydrofuran at -10℃; for 0.166667 h;
A mixture of 4-bromobenzaldehyde (300.0 g, 1620.0 mmol) and amino acetaldehyde dimethyl acetal (170.4 g, 1620 mmol) in anhydrous toluene (1.5 L) was refluxed under a Dean-Stark condenser for 12 h. The solution was concentrated under vacuum. The residue was dissolved in anhydrous THF and cooled to -10 °C. Ethyl chloroformate (193.3 ml_, 1782 mmol) was added and stirred for 10 min at -10 °C, and then allowed to warm to room temperature. Subsequently trimethyl phosphite (249.6 ml_, 1782.0 mmol) was added dropwise to the reaction mixture and stirred for 10 h at room temperature. The solvent was evaporated under vacuum and the residue was dissolved in anhydrous DCM (1.5 L) and stirred for 30 minutes. The reaction mixture was cooled to 0 °C, and titanium tetrachloride (1.2 L, 6480 mmol) was added dropwise. The reaction mixture was stirred at 40 °C for 6 days. The reaction mixture was poured into ice and pH was adjusted to 8 - 9 with aqueous 6N NaOH solution. The suspension was extracted three times with EtOAc. The organic layer was extracted with 3 M HCI. The acidic aqueous solution was adjusted to pH to 7 - 8 with 3N NaOH solutions and extracted two times with EtOAc. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to provide the product. Crude compound was dissolved in minimum amount of DCM and mixed with pentane to get compound A1 as light brown solid. Yield: 90 g (35percent). Rf: 0.6 (30percent EtOAc in petroleum ether). LCMS m/z = 209 (M + 1 ). 1H NMR (400 MHz, cf6-DMSO): δ 7.82 (m, 2H), 8.1 1 (d, J = 8.8 Hz, 2H), 8.30 (br s, 1 H), 8.56 (d, J = 6.0 Hz, 1 H), 9.35 (s, 1 H).
14%
Stage #1: at 120℃; Dean-Stark
Stage #2: at 160℃; for 0.5 h;
General procedure: Aminoacetaldehyde dimethylacetal (3.0 eq.) was added to a solution of bromobenzaldehyde13b or 13c (1.0 eq.) in toluene (30 mL). Each reaction mixture was refluxed (Dean–Stark apparatus)at 120 °C. After consumption of the starting material, each reaction mixture was concentrated todryness, then dissolved in conc. H2SO4 (2 mL) and added to a cold solution of P2O5 in conc. H2SO4(0.5 mL). Each reaction mixture was heated at 160 °C for 30 min, allowed to cool to RT, neutralizedwith NaOH (10 M), extracted with EtOAc, and concentrated to dryness. Each residue was subjected toFCC to afford 6-bromoisoquinoline (14b, 30 mg, 0.14 mmol, 14percent) and 7-bromoisoquinoline (14c, 99 mg,0.47 mmol, 22percent) [20,21]. Ethylchloroformate (1.0 eq.) was added to a solution of isoquinoline 14b or14c (1.0 eq.) in DCM at 0 °C and stirred at the same temperature for 30 min, followed by additionof 2-trimethylsilylthiazole (1.0 eq.). Each reaction mixture was stirred at RT for 3 h, concentratedto dryness, and each residue was subjected to FCC. Each product was dissolved in benzene (5 mL),o-chloranil (1.0 eq.) was added, and each reaction mixture was refluxed for 5 h. Each reaction mixturewas diluted with 5percent NaOH (10 mL), extracted with DCM, and concentrated to dryness. Each reactionmixture residue was subjected to FCC to afford the products 9b and 9c.6-Bromo-1-(2-thiazolyl)isoquinoline (9b): 6-Bromoisoquinoline (14b, 30 mg, 0.14 mmol) was synthesizedstarting from 4-bromobenzaldehyde (13c, 200 mg, 1.08 mmol) in 14percent yield. Compound 9b wassynthesized starting from 6-bromoisoquinoline (14b, 100 mg, 0.48 mmol) in 15percent yield over two steps(21 mg, 0.07 mmol), obtained as an orange powder, m.p. 103–105 °C.
Reference: [1] Patent: WO2015/181676, 2015, A1, . Location in patent: Page/Page column 132-133
[2] Dalton Transactions, 2015, vol. 44, # 18, p. 8552 - 8563
[3] Molecules, 2017, vol. 22, # 8,
[4] Journal of the Chemical Society. Perkin Transactions 2, 1998, # 2, p. 437 - 447
  • 10
  • [ 63927-21-9 ]
  • [ 34784-05-9 ]
YieldReaction ConditionsOperation in experiment
1.2% With phosphorus pentoxide In sulfuric acid at 160℃; for 2 h; Preparation Example G-1. Isoquinoline-6-carboxylic acid A solution prepared by adding (4-bromobenzylydene)-(2,2-diethoxyethyl) amine (synthesized from 4-bromobenzaldehyde, according to the method described in J. Org. Chem., vol. 48, 3344-3346 (1983)) (51.4g, 0.189mmol) to an ice-cold concentrated sulfuric acid (20g) was added to a solution prepared by adding diphosphorus pentoxide (40g) to an ice-cold concentrated sulfuric acid (360g), and the solution was stirred at 160°C for 2 hours. The reaction solution was gradually cooled to 0°C, the solution was filtered through Celite pad, the filtrate was neutralized with sodium carbonate. This solution was further filtrated through Celite pad, this filtrate was extracted with ethyl acetate and dried over anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate), and 6-bromoisoquinoline (482mg, 1.2percent) was obtained as an orange oil. Next, to a solution of 6-bromoisoquinoline (382mg, 1.84mmol) in N,N-dimethylformamide (3.8mL) were added zinc cyanide (431 mg, 3.67mmol) and tetrakis(triphenylphosphine)palladium(0) (42mg, 0.0367mmol) under nitrogen atmosphere, and the mixture was stirred at 100°C for 1 hour. Tetrakis(triphenylphosphine)palladium(0) (42mg, 0.0367mmol) was further added, and the mixture was stirred for 2.5 hours at 100°C. The reaction mixture was allowed to room temperature, ethyl acetate and water were added for extraction, the organic layer was washed with water and dried over anhydrous magnesium sulfate. The residue was purified by silica gel column chromatography (hexane : ethyl acetate), and isoquinoline-6-carbonitrile (234mg, 83percent) was obtained as a yellow solid. Lastly, isoquinoline-6-carbonitrile (51mg, 0.331 mmol) was dissolved in diethyleneglycol (1.0mL), potassium hydroxide (9mg, 0.166mmol) was added thereto, followed by stirring at 160°C for 3 hours. The reaction mixture was allowed to room temperature, neutralized using hydrochloric acid, extracted with ethyl acetate, dried over anhydrous magnesium sulfate, then, the solvent was evaporated. Water was added to the residue, the precipitated solid was collected, washed with water, dried in vacuo, so as to obtain the title compound (12mg, 21 percent) as a yellow solid.
1.2% With phosphorus pentoxide In sulfuric acid at 0 - 160℃; for 2 h; A solution prepared by adding (4-bromobenzylydene)-(2,2-diethoxyethyl) amine (synthesized from 4-bromobenzaldehyde, according to the method described in J. Org. Chem., vol. 48, 3344-3346 (1983)) (51.4g, 0.189mmol) to an ice-cold concentrated sulfuric acid (20g) was added to a solution prepared by adding diphosphorus pentoxide (40g) to an ice-cold concentrated sulfuric acid (360g), and the solution was stirred at 160°C for 2 hours. The reaction solution was gradually cooled to 0°C, the solution was filtered through Celite pad, the filtrate was neutralized with sodium carbonate. This solution was further filtrated through Celite pad, this filtrate was extracted with ethyl acetate and dried over anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate), and 6-bromoisoquinoline (482mg, 1.2percent) was obtained as an orange oil. Next, to a solution of 6-bromoisoquinoline (382mg, 1.84mmol) in N,N-dimethylformamide (3.8mL) were added zinc cyanide (431mg, 3.67mmol) and tetrakis(triphenylphosphine)palladium(0) (42mg, 0.0367mmol) under nitrogen atmosphere, and the mixture was stirred at 100°C for 1 hour. Tetrakis(triphenylphosphine)palladium(0) (42mg, 0.0367mmol) was further added, and the mixture was stirred for 2.5 hours at 100°C. The reaction mixture was allowed to room temperature, ethyl acetate and water were added for extraction, the organic layer was washed with water and dried over anhydrous magnesium sulfate. The residue was purified by silica gel column chromatography (hexane : ethyl acetate), and isoquinoline-6-carbonitrile (234mg, 83percent) was obtained as a yellow solid. Lastly, isoquinoline-6-carbonitrile (51mg, 0.331 mmol) was dissolved in diethyleneglycol (1.0mL), potassium hydroxide (9mg, 0.166mmol) was added thereto, followed by stirring at 160°C for 3 hours. The reaction mixture was allowed to room temperature, neutralized using hydrochloric acid, extracted with ethyl acetate, dried over anhydrous magnesium sulfate, then, the solvent was evaporated. Water was added to the residue, the precipitated solid was collected, washed with water, dried in vacuo, so as to obtain the title compound (12mg, 21 percent) as a yellow solid.
Reference: [1] Patent: EP1782811, 2007, A1, . Location in patent: Page/Page column 58
[2] Patent: EP1669348, 2006, A1, . Location in patent: Page/Page column 66
[3] Tetrahedron, 2009, vol. 65, # 48, p. 10009 - 10015
  • 11
  • [ 33065-61-1 ]
  • [ 34784-05-9 ]
Reference: [1] Journal of Organic Chemistry, 1980, vol. 45, # 26, p. 5312 - 5315
[2] Bioorganic and Medicinal Chemistry Letters, 2002, vol. 12, # 5, p. 827 - 832
[3] Patent: WO2006/52555, 2006, A2, . Location in patent: Page/Page column 31; 66-67
  • 12
  • [ 1036378-91-2 ]
  • [ 34784-05-9 ]
Reference: [1] Patent: WO2008/77552, 2008, A1, . Location in patent: Page/Page column 53
[2] Patent: WO2008/77553, 2008, A1, . Location in patent: Page/Page column 42
[3] Patent: US2010/56566, 2010, A1, . Location in patent: Page/Page column 15
  • 13
  • [ 1036378-89-8 ]
  • [ 34784-05-9 ]
YieldReaction ConditionsOperation in experiment
12%
Stage #1: With chlorosulfonic acid In dichloromethane at -20 - 45℃; for 10 h;
Stage #2: With sodium hydrogencarbonate In dichloromethane; waterCooling with ice
Step 2To a stirred solution of N-(4-bromobenzyl)-2,2-dimethoxyethanamine (10 g, 0.037 mol) in CH2C12 (100 mL) was added C1S03H (21.3 g, 0.18 mol) at -20 °C dropwise. The resulting reaction mixture was allowed to stir at 45 °C for 10 h. The resulting reaction mixture was diluted with CH2C12 and ice cold H20, then neutralized with aqueous NaHC03. The organic layer was separated and aqueous layer extracted with CH2C12. The combined organic layers were dried over Na2S04 and concentrated at reduced pressure to get crude 6- bromoisoquinoline, which was purified by silica gel chromatography eluting with 5-15 percent EtOAc-hexanes to afford 6-bromoisoquinoline (0.9 g, 12 percent) as yellow liquid
Reference: [1] Patent: WO2011/103196, 2011, A1, . Location in patent: Page/Page column 76
  • 14
  • [ 226942-29-6 ]
  • [ 34784-05-9 ]
  • [ 1393714-90-3 ]
Reference: [1] Advanced Synthesis and Catalysis, 2017, vol. 359, # 14, p. 2358 - 2363
  • 15
  • [ 34598-49-7 ]
  • [ 34784-05-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2002, vol. 12, # 5, p. 827 - 832
  • 16
  • [ 34598-50-0 ]
  • [ 34784-05-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2002, vol. 12, # 5, p. 827 - 832
  • 17
  • [ 1122-91-4 ]
  • [ 34784-05-9 ]
Reference: [1] Patent: WO2011/103196, 2011, A1,
  • 18
  • [ 1009309-65-2 ]
  • [ 34784-05-9 ]
Reference: [1] Journal of Physical Chemistry, 1993, vol. 97, # 17, p. 4540 - 4547
  • 19
  • [ 34784-05-9 ]
  • [ 1075-11-2 ]
Reference: [1] Journal of the American Chemical Society, 2014, vol. 136, # 10, p. 3792 - 3795
  • 20
  • [ 34784-05-9 ]
  • [ 205055-63-6 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 12, p. 3227 - 3230
[2] Bioorganic and Medicinal Chemistry Letters, 1999, vol. 9, # 5, p. 685 - 690
[3] Patent: WO2013/185353, 2013, A1,
[4] Patent: WO2014/159733, 2014, A1,
[5] Patent: WO2014/165232, 2014, A1,
[6] Patent: US2015/119387, 2015, A1,
[7] European Journal of Organic Chemistry, 2016, vol. 2016, # 8, p. 1606 - 1611
[8] Patent: WO2016/191525, 2016, A1,
[9] Patent: JP2017/95498, 2017, A,
[10] Patent: CN106831576, 2017, A,
[11] Patent: CN104530042, 2017, B,
  • 21
  • [ 34784-05-9 ]
  • [ 215453-26-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 1999, vol. 9, # 5, p. 685 - 690
  • 22
  • [ 34784-05-9 ]
  • [ 82827-09-6 ]
Reference: [1] Patent: US2004/44258, 2004, A1, . Location in patent: Page 159-160
  • 23
  • [ 34784-05-9 ]
  • [ 170097-67-3 ]
Reference: [1] Patent: EP3192791, 2017, A1,
[2] European Journal of Medicinal Chemistry, 2019, p. 317 - 333
  • 24
  • [ 34784-05-9 ]
  • [ 226942-29-6 ]
YieldReaction ConditionsOperation in experiment
67.2% at 10 - 35℃; for 1.5 h; NaBH4 (3.46 g, 91.51 mmol) was slowly added to a mixture of 6-bromoisoquinoline (4.76 g, 22.88 mmol) and acetic acid (90 mL) at room temperature, and the mixture was stirred at room temperature for 1.5 hr.
To the reaction mixture was added water, and the mixture was adjusted to pH 8 with 8N aqueous sodium hydroxide solution.
The mixture was extracted 3 times with ethyl acetate/THF mixed solution (3:1).
The organic layer was washed with water, dried over magnesium sulfate, and the solvent was evaporated under reduced pressure.
The residue was purified by silica gel column chromatography (NH, solvent gradient; 20→90percent ethyl acetate/hexane) to give 6-bromo-1,2,3,4-tetrahydroisoquinoline (3.26 g, 15.37 mmol, 67.2percent) as a colorless oil.
1H NMR (300 MHz, CDCl3):δ 1.63(1H,s), 2.77(2H,t,J=6.0 Hz), 3.11(2H,t,J=5.9 Hz), 3.95(2H,s), 6.85-6.90(1H,m), 7.21-7.26(2H,m).
Reference: [1] Patent: EP3192791, 2017, A1, . Location in patent: Paragraph 0593
[2] Patent: WO2013/80222, 2013, A1, . Location in patent: Page/Page column 39
[3] Applied Catalysis A: General, 2018, vol. 560, p. 37 - 41
  • 25
  • [ 34784-05-9 ]
  • [ 893566-74-0 ]
Reference: [1] Patent: WO2013/80222, 2013, A1,
[2] Patent: EP3192791, 2017, A1,
  • 26
  • [ 34784-05-9 ]
  • [ 1082674-24-5 ]
Reference: [1] Patent: WO2015/181676, 2015, A1,
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 34784-05-9 ]

Bromides

Chemical Structure| 34784-04-8

[ 34784-04-8 ]

5-Bromoisoquinoline

Similarity: 0.92

Chemical Structure| 81045-39-8

[ 81045-39-8 ]

5,8-Dibromoisoquinoline

Similarity: 0.90

Chemical Structure| 129013-83-8

[ 129013-83-8 ]

3-(4-Bromophenyl)pyridine

Similarity: 0.90

Chemical Structure| 4373-72-2

[ 4373-72-2 ]

4-(3-Bromophenyl)pyridine

Similarity: 0.90

Chemical Structure| 891785-28-7

[ 891785-28-7 ]

6-Bromoisoquinolin-3-amine

Similarity: 0.88

Related Parent Nucleus of
[ 34784-05-9 ]

Isoquinolines

Chemical Structure| 34784-04-8

[ 34784-04-8 ]

5-Bromoisoquinoline

Similarity: 0.92

Chemical Structure| 81045-39-8

[ 81045-39-8 ]

5,8-Dibromoisoquinoline

Similarity: 0.90

Chemical Structure| 891785-28-7

[ 891785-28-7 ]

6-Bromoisoquinolin-3-amine

Similarity: 0.88

Chemical Structure| 58794-09-5

[ 58794-09-5 ]

7-Bromoisoquinoline

Similarity: 0.88

Chemical Structure| 63927-22-0

[ 63927-22-0 ]

8-Bromoisoquinoline

Similarity: 0.87

; ;